A new combination capsule for BPH

Combodart (dutasteride/tamsulosin) is now available for the management of benign prostatic hyperplasia.


Dutasteride delays progression of BPH by inhibiting the production of the hormone dihydrotestosterone (DHT) that stimulates prostate growth. Tamsulosin provides rapid symptom relief by reducing smooth muscle tone in the prostate and bladder neck.


A four-year multicentre, randomised, double-blind study in 4844 men assessed the efficacy of combination therapy with dutasteride and tamsulosin versus monotherapy with either agent in reducing the relative risk of acute urinary retention (AUR), BPH-related surgery, and BPH clinical progression over four years in men at increased risk of progression.

Combination therapy was significantly superior to tamsulosin monotherapy, but not dutasteride monotherapy, at reducing relative risk of AUR or BPH-related surgery. Combination therapy was significantly superior to both monotherapies at reducing the relative risk of BPH clinical progression, and provided greater symptom relief at four years.

Safety and tolerability of combination therapy was consistent with that of monotherapies, except for cardiac failure, which was higher in the combination and tamsulosin groups.1

View Combodart drug record


  1. Roehrborn C et al. Eur Urol 2010; 57: 121-31.

Further information: GSK

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more